Shares of Gossamer Bio jumped 11.5% in pre-market trading Monday after boutique investment bank Chardan initiated coverage with a Buy rating and an eye-popping $160 price target — roughly 15 times the current share price. For a company with a market cap of just $56.76 million and no approved product, the call is either visionary or reckless. Here's what investors need to parse.
The Drug Missed Its Big Test, but Chardan Is Betting on Approval Anyway
Chardan's $160 target assumes a 65% probability that the FDA approves seralutinib, projecting roughly $1.3 billion in peak revenue by 2035 — an inhaled therapy for pulmonary arterial hypertension (PAH), a rare, life-threatening condition that restricts blood flow in the lungs. The catch: seralutinib's pivotal trial showed a walk-distance improvement of +13.3 meters over placebo, but its p-value of 0.0320 missed the stricter pre-set statistical threshold of 0.025 . In plain terms, the drug showed a signal, but not convincingly enough by the study's own rules.
The FDA Left the Door Open — Barely
The NDA filing rests on the Phase 3 study as the primary trial, with confirmatory data from an earlier Phase 2 study, following a June 2026 Pre-NDA meeting in which the FDA framed key efficacy questions as review issues rather than filing barriers . If accepted for filing, seralutinib could be eligible for an FDA approval decision in the third quarter of 2027 . That timeline makes this a long, binary bet: approval would transform the company; rejection could be fatal.
The Balance Sheet Is Burning Fast
Gossamer has negative free cash flow of $162.63 million , and its stock needed a 1-for-80 reverse stock split, effective September 10, 2026 , just to stay listed on Nasdaq. Approval would unlock up to $100 million more via warrants , but without it, funding becomes an existential question.
Chardan Stands Alone at the High End
Leerink recently upgraded Gossamer to Outperform on positive FDA feedback, but H.C. Wainwright, also a bull, maintains just a $2 price target . Chardan's $160 is not a typo — it's a model built on peak revenue a decade away, discounted by a coin-flip approval probability. Chardan called Gossamer its top small-cap pick for 2027 , but investors should note this is a pre-revenue company whose sole asset stumbled at the finish line of its main clinical trial. The upside is real if the FDA says yes; the downside is a cash-starved company with nothing else in the pipeline.